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Abstract 
The metabolism of cholesterol sulfate (CS) was investigated in immortalized, Epstein-Barr virus-transformed lymphoid cell lines 
derived from normal individuals and patients affected with recessive X-linked ichthyosis (XLI). Normal lymphoid cells expressed 
arylsulfatase C and steroid sulfatase (including cholesterol sulfatase) activities, and these two sulfohydrolases showed the same enzyme 
properties as in other human cells, e.g., leukocytes or skin fibroblasts. XLI-derived lymphoid cell lines exhibited extremely deficient 
activity of both arylsulfatase C and steroid sulfatase. While normal and XLI intact, living lymphoid cells could take up exogenous 
radiolabelled CS through a non-receptor-mediated process, XLI cells were completely unable to degrade CS to cholesterol. However, 
despite their defect in CS degradation, steroid sulfatase-deficient cells did not accumulate CS because of outflux of this sterol. The 
potential implications of these findings to the pathogenesis of increased CS content in plasma and epidermis of XLI patients are 
discussed. This study also demonstrates that immortalized lymphoid cell lines may represent a useful experimental model system for the 
study of XLI. 
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1. Introduction 
X-Linked Ichthyosis (XLI) is an inborn skin disorder, 
transmitted as a sex-linked recessive trait and characterized 
by the deficient activity of steroid sulfatase (STS, EC 
3.1.6.2), an enzyme which acts on the sulfate group from 
the 3-position of sterols or steroids [1-4]. This microsomal 
enzyme is identical [4-7] with the s-form of arylsulfatase 
C (ASC, EC 3.1.6.1) which hydrolyzes artificial colored 
compounds or fluorogenic substrates as 4-methylumbel- 
liferyl sulfate [4,8]. STS deficiency during fetal life results 
in low estrogen production by the placenta nd is associ- 
ated with low maternal estrogen excretion, cervical dysto- 
cia and delayed delivery [2,3]. Expression of the enzyme 
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defect during postnatal life (between birth and 4 months of 
age) is accompanied by the development of an ichthyosis 
with prominent dark scales and corneal opacities [2]. Defi- 
cient activity of STS and ASC has been demonstrated in 
blood leukocytes [9-12], hair follicles [13,14], cultured 
skin fibroblasts [15-17], amniotic fluid cells [18] and 
keratinocytes [19] from patients affected with XLI. 
STS deficiency, as well as ichthyosis, is also found in a 
rare inherited disorder called multiple sulfatase deficiency 
(MSD) [1,2]. In these STS-deficient conditions, the disor- 
der of keratinization is believed to result from the absence 
of degradation of cholesterol sulfate (CS) and its subse- 
quent accumulation i intercellular domains of the stratum 
corneum [20,21]. CS might induce the scaling abnormality 
through alterations of lipid metabolism [22,23] and modifi- 
cations of the lipid microenvironment [24]. However, the 
reason why CS accumulates in the extracellular space, i.e., 
in epidermis, as well as in plasma [25,26], still remains 
unclear. 
Experimental models proved essential for biochemical 
and genetic studies of inherited metabolic diseases. Up to 
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now, only human skin fibroblasts [2,7,22] and keratino- 
cytes [27] have been used as an experimental model in 
culture for the study of XLI. Another potential model 
system in culture is represented by Epstein-Barr virus- 
transformed lymphoid cell lines (LCL) [28]. LCL consti- 
tute a new cellular model system which has some advan- 
tages over cultured skin fibroblasts: unlimited lifespan, 
continuous cell culture without senescence, short doubling 
time, growth in suspension [28,29]. LCL have proved 
useful for studying various lysosomal genetic disorders 
[30-36]. 
In this paper, we first tested the suitability of LCL 
established from patients affected with XLI and MSD as 
an experimental model to study XLI. We next investigated 
the metabolic fate of CS in normal and XLI-derived LCL. 
We show for the first time that, despite their inability to 
degrade CS, these STS-deficient cells do not accumulate it.
2. Materials and methods 
2.1. X-Linked ichthyosis patients 
Patients (C.S., aged 14; D.R., aged 3; G.A., aged 8; and 
M.P., aged 15) were Caucasian with skin color type III-IV. 
They presented with large, dark scales most apparent on 
the upper and lower limbs and trunk. There was a sparing 
of the palms and soles, and a marked clearing in the 
summer. During the winter, some patients were treated 
with etretinate (Tigason * Roche). Informed consent was 
obtained from all patients. 
2.2. Chemicals 
4-Methylumbelliferyl sulfate, 4-methylumbelliferone, 
4-methyl-umbelliferyl-/3-D-galactopyranoside, Ficoll- 
Histopaque and dehydroepiandrosterone sulfate (DHEAS) 
were obtained from Sigma (St. Louis, MO). [7-3H]Dehy - 
droepiandrosterone sulfate ([7-3H]DHEAS; spec. act. 16 
Ci/mmol) and [1,2-3H]cholesterol (48 Ci/mmol) were 
supplied from Du Pont NEN (Les Ulis, France). RPMI 
1640 medium, fetal calf serum, streptomycin, penicillin, 
glutamine and Ultroser HY were from Gibco BRL (Cergy 
Pontoise, France). All other chemicals and solvents were 
from Merck (Darmstadt, FRG). 
2.3. Synthesis of [ 3H]cholesterol sulfate 
Radioactive CS was synthesized from [l,2- 
3H]cholesterol according to the procedure described by 
Bleau et al. [37] and purified by TLC using 
chloroform/methanol/water (100:42:6, by vol.) as devel- 
oping solvent. Radiolabelled CS was stored at -20°C in 
chloroform/methanol (2:1, by vol.) solution. The assign- 
ment of the synthesized compound to CS was based upon 
several criteria including: (1) cochromatography with the 
authentic standard; (2) characteristic reddish coloration of 
the band on TLC upon sulfuric acid treatment; (3) genera- 
tion of cholesterol after enzymatic hydrolysis by ho- 
mogenates of normal cells, and (4) virtual absence of 
degradation by homogenates of XLI cells. 
2.4. Isolation of leukocytes 
Leukocytes from heparinized blood of control subjects 
and XLI patients were isolated [38] using Plasmagel c": 
(Roger Bellon Lab., Paris, France). 
2.5. Cell culture 
Human skin fibroblasts were obtained from one of the 
XLI patients referred to our department (G.A.) and from 
specimens ubmitted to our laboratory for diagnostic pur- 
poses. Primary cultures were established from forearm 
biopsies. Fibroblasts (85RD322 and 85RD513) from two 
XLI patients were kindly provided by Dr. W.J. Kleijer 
(Erasmus University, Rotterdam, The Netherlands). LCL 
were established by Epstein-Barr virus-transformation f 
blood B lymphocytes obtained from control individuals 
and from XLI patients (C.S., D.R., G.A., M.P.) as previ- 
ously described [29]. LCL from patients with MSD (GM 
3246 and GM 4916) and familial hypercholesterolemia 
(GM 1767, GM 1459) were purchased from the NIGMS 
Human Genetic Mutant Cell Repository (Coriell Institute, 
Camden, N J). Fibroblasts and LCL were grown in a 
humidified 5% CO 2 atmosphere at 37°C in RPMI 1640 
medium supplemented with L-glutamine (2 mmol/l), peni- 
cillin (100 U/ml), streptomycin (100 /~g/ml) and heat-in- 
activated fetal calf serum (10%) as previously reported 
[32,35]. Fibroblasts were studied between the eighth and 
eighteenth passages. After washing with PBS, confluent 
fibroblasts were scraped from the flasks with a rubber 
policeman; LCL were harvested by slow-speed centrifuga- 
tion. Cell pellets were kept frozen at -70°C until use. 
2.6. Enzyme assays 
Cell pellets were suspended in a small volume of 1 
mg/ml Triton X-100 and briefly sonicated (3 × 15 s, 
Soniprep MSE sonicator). ASC activity was assayed with 
4-methylumbelliferyl-sulfate [11].STS activity was deter- 
mined with [7-3H]DHEAS as substrate using a modifica- 
tion of the procedure of Epstein et al. [9]. Released [7- 
3H]DHEA was extracted by 2 ml scintillation fluid In- 
stafluor ® (Packard, IL) for counting (Packard 4530 scintil- 
lation counter). Hydrolysis of 4-methylumbelliferyl-sulfate 
and [3H]DHEAS by LCL homogenates was linear with 
protein concentration at least up to 54 /xg per assay. 
Cholesterol sulfatase was assayed using [3H]CS essentially 
as described for STS. After 4 h incubation at 37°C, the 
reactions were stopped by adding 1.5 ml methanol and 
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2.25 ml hexane. After mixing and centrifuging, 1.5 ml of 
the hexane phase (containing the liberated [3H]cholesterol) 
was mixed with 5 ml Instafluor ® and counted. /3-Galacto- 
sidase activity was determined fluorometricaily [33]. The 
enzyme activities of different cell strains were compared 
by assaying the hydrolases on the same day. Each determi- 
nation was carried out at least in duplicate, the deviation 
being no greater than 5%. Protein content was determined 
[39] using bovine serum albumin as standard. 
2. 7. Cholesterol sulfate uptake and metabolic studies 
LCL were preincubated in RPMI 1640 medium contain- 
ing 2% Ultroser HY, a serum substitute devoid of lipopro- 
teins. After two days, the experiments were initiated. A 
chloroform/methanol (2:1, by vol.) solution of the radiola- 
belled CS was evaporated under nitrogen. The residue was 
dissolved in a small volume of dimethylsulfoxide and 
mixed with sterile culture medium containing either 10% 
fetal calf serum or only 2% Ultroser. These media were 
warmed at 37°C for about 15 min and added to the 
cultured cells. The final concentration f CS in the incuba- 
tion medium was usually about 10 6 dpm/ml  (i.e., 10 
pmol/ml).  The final concentration of dimethylsulfoxide 
did not exceed 0.7% (by vol.). In some experiments, 
unlabelled CS or human serum low-density lipoproteins 
were included in the incubation medium. After incubating 
the cells for varying periods at 37°C, the experiments were 
terminated by removal of the culture medium and LCL 
were harvested by slow-speed centrifugation. Cells were 
washed three times with PBS containing bovine serum 
albumin (2 mg/ml) ,  and then twice with PBS alone, and 
the cell pellets stored at -20°C.  
In 'pulse-chase' xperiments, cells were incubated for 
24 h with the radiolabelled CS in the presence of fetal calf 
serum. After removal of the incubation medium, cells were 
washed twice with complete medium and further incubated 
for the indicated times in medium devoid of radioactive 
CS. At the end of the chase periods, cells were processed 
as mentioned above. 
Table 1 
Enzyme activities ofarylsulfatase C (ASC) and steroid sulfatase (STS) in leukocytes, cultured skin fibroblasts and lymphoid cell lines 
Enzyme source Sex Enzyme activity (nmol/h.mg protein) 
ASC STS fl-Gal 
Leukocytes: 
Controls M 0.270 + 0.130 0.136 188 + 58 
(~]) (3) Ol) 
Controls F 0.300 + 0.010 0.124 167 + 56 
(13) (3) (13) 
XLI hemizygotes M 
C.S. 0.033 
G.A. 0.040 0 252 
M.P. 0.027 0 170 
Skin fibroblasts: 
Controls M 3.120 + 0.570 1.220 + 0.610 2786 
(3) (3) (1) 
Controls F 8.660 + 5.830 ( 3.210 + 2.050 122 + 1088 
(8) (5) (5) 
XLI hemizygotes M 
G.A. 0.050 0 534 
85RD322 0.160 0 2184 
85RD513 0 0 576 
Lymphoid cell lines: 
Controls M 1.200 + 0.950 0.360 + 0.280 165 + 44 
(3) (3) (3) 
F 1.980 + 1.150 0.500 + 0.260 154 + 81 
(7) (6) (6) 
XLI hemizygotes M 
C.S. 0.014 
D.R. 0.040 
G.A. 0.008 0.002 88 
M.P. 0.004 0.009 69 
MSD M 0.035 0.006 176 
(2) (2) (2) 
Controls 
Enzyme activities (mean-t-S.D.) were determined with natural and synthetic substrates a described in Section 2. Each enzyme determination was 
performed at least in duplicate and on different cell batches. In brackets, number of different individuals tested, fl-Galactosidase (/3-Gal) activity was 
measured asa control enzyme. 
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2.8. Lipid extraction and analyses 
Cell pellets were suspended in 0.6 ml of distilled water 
and sonicated in ice for 3 × 15 s. An aliquot was taken for 
protein determination; another one was counted in a scin- 
tillation spectrometer using Picoftuor ® 15 to determine the 
amount of total cell-associated radioactivity. The remain- 
ing was extracted with 2.5 ml of chloroform/methanol 
(2:1, by vol.) [40], vortex mixed and centrifuged at 1000 × 
g for 15 min. After evaporating the lower phase under a 
nitrogen stream, the residue was dissolved in a small 
volume of chloroform/methanol (2:1, by vol.), the lipids 
resolved by analytical TLC in chloroform/methanol/water 
(100:42:6, by vol.) and the plate analyzed using a Berthold 
(Tracemaster 20) TLC radiochromatoscan. Identification of 
the radiolabelled metabolites was performed by comparing 
their R v with those of authentic ommercial standards. 
3. Results 
3.1. ASC and STS activities in LCL homogenates 
described in the present study, thereby confirming the 
diagnosis of XLI for these patients. 
In normal LCL, the activity of ASC and STS was 3-6 
times higher than in leukocytes. Whereas apparent differ- 
ences were noted in the mean activities of ASC and STS 
between males and females, these were not found to be 
significant (even when related to the control hydrolase, 
/3-galactosidase), xcept for the ASC activities in normal 
skin fibroblasts (P < 0.05; U-test of Mann and Whitney). 
Despite some interindividual variations observed both for 
ASC and STS activities in control lymphoid cells, the two 
enzyme activities were virtually undetectable in LCL from 
four XLI patients. LCL from MSD patients also showed 
considerably reduced values for the activity of ASC and 
STS (Table 1). 
The activity of cholesterol sulfatase was also deter- 
mined in LCL homogenates: while this activity averaged 
1.6 nmol /h /mg in control cells, it was almost unde- 
tectable in XLI cell homogenates (data not shown). 
3.2. Effect ~)f pH and phosphate ions on ASC and STS 
acti~,ities in LCL 
The activity of ASC and STS was determined under 
well-established experimental conditions in different lines 
of LCL derived from normal individuals and XLI patients. 
Table 1 compares these activities in LCL with those in 
peripheral blood leukocytes and cultured skin fibroblasts. 
The specific ASC and STS activities we measured in 
leukocytes and fibroblasts are in good agreement with 
previous observations [12,17,18]. As described [9-12,15- 
18,41], both ASC and STS activities in leukocytes and 
fibroblasts from XLI patients were severely reduced or 
even undetectable. These mutant cells included two fibrob- 
last lines from previously diagnosed XLI patients 
(85RD322 and 85RD513) and cells from three patients 
To further characterize the LCL as a new model for the 
study of XLI, some enzyme properties of ASC and STS 
were investigated on these cultured cells. As shown in Fig. 
1, in the absence of phosphate ions, a peak of ASC activity 
was detected at about pH 6.5 and most probably corre- 
sponded to the contribution by the acidic lysosomal sulfa- 
tases which are also able to cleave 4-methyl-umbelliferyl 
sulfate. Indeed, under these conditions, cells from XLI 
patients also exhibited some activity. Addition of phos- 
phate resulted in complete inhibition of the activity of 
other sulfatases than ASC. Thus, in the presence of phos- 
phate ions, the ASC activity in control cells peaked at pH 
8.0 and was completely deficient in XLI LCL. STS activ- 
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Fig. 1. pH Dependence of arylsulfatase C (ASC) and steroid sulfatase (STS) activities in normal and XLI lymphoid cell lines. Enzyme activities were 
determined as described in Section 2 on homogenates of normal (open symbols) and XLI (closed symbols) LCL in the absence (squares) or presence 
(triangles) of phosphate ions, using 0.1 mol/I of the following buffers: citrate or citrate-phosphate for pH 5.0-6.5, and Tris-chloride or phosphate for pH 
7.0-8.5. Each point corresponds to a triplicate and duplicate determination for ASC and STS, respectively. 
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Fig. 2. Uptake of [3H]cholesterol sulfate by LCL as a function of incubation time. Intact LCL from normal individuals, low-density lipoprotein 
receptor-deficient (familial hypercholesterolemia; FH) patients and XLI patients were incubated with [3H]cholesterol sulfate (about 10 pmol/ml) in 
medium supplemented with 2% Ultroser HY (A) or 10% fetal calf serum (FCS; B). At the indicated time periods, cells were collected, washed and the total 
cell-associated radioactivity determined as described in Section 2. 
ity showed a pH optimum at about 7.5 and was partially 
inhibited by phosphate ions (Fig. 1). No STS activity could 
be detected in LCL from patients with XLI, with or 
without phosphate buffer. 
3.3. Uptake of cholesterol sulfate by LCL 
To investigate the mode of uptake of CS by LCL, we 
studied the effect of incubation time and CS concentration 
in the culture medium on the amount of cell-associated 
lipid. To examine further the possible role of lipoproteins 
in CS uptake, cells were incubated in the presence or 
absence of fetal calf serum. Since CS is carried by lipopro- 
teins [26], the possibility that CS could be delivered to the 
cells in a lipoprotein-associated form was investigated by 
studying its uptake by familial hypercholesterolemia cells 
lacking the low-density lipoprotein-receptor. 
As illustrated in Fig. 2, the amount of cell-associated 
CS increased with incubation time up to 24 h and then 
remained stable, possibly indicating some exchange of CS 
with the extracellular medium. Some differences in rates of 
CS uptake were observed when varying cell density (data 
not shown). However, no difference in CS uptake was 
found between the different cell lines tested and, in panic- 
A. Ultroser B. lO s "I ~,'~,g 60 • xu / /  60 FCS= 1°2~J~ - l °s "  I J~l 
.=  o / / -  ,o = n.O 4 10~' lb3' 165 
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Fig. 3. Uptake of cholesterol sulfate by LCL as a function of its extracellular concentration. I tact LCL from normal individuals, low-density lipoprotein 
receptor-deficient (familial hypercholesterolemia; FH) patients and XLI patients were incubated with increasing amounts of [3H]cholesterol sulfate in 
medium supplemented with 2% Ultroser HY (A) or 10% fetal calf serum (B). In inset, the medium contained [3H]cholesterol sulfate (about l06 dpm/ml) 
and unlabelled cholesterol sulfate at the indicated concentration. After 24 h incubation, cells were collected, washed and the total cell-associated 
radioactivity determined as described in Section 2 (the inset gives the total cell-associated CS). 
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Fig. 4. Degradation of cholesterol sulfate by LCL as a function of its extracellular concentration. Intact LCL from normal individuals, low-density 
lipoprotein receptor-deficient (familial hypercholesterolemia; FH) patients and XLI patients were incubated for 24 h with increasing amounts of 
[3H]cholesterol sulfate in medium supplemented with 2% Ultroser HY (A) or 10% fetal calf serum (B). After washing the cells, the cellular lipids were 
extracted, separated and the [3H]cholesterol formed quantified by TLC as described in Section 2. 
ular, between normal and familial hypercholesterolemia 
LCL, suggesting that CS became associated with the cells 
via a low-density lipoprotein receptor-independent path- 
way (Fig. 2). 
When CS was administered to the cells in medium 
containing Ultroser, i.e., in the absence of lipoproteins 
(Fig. 2A), the amount of cell-associated CS was about 2-3 
times higher than in the presence of serum (Fig. 2B). This 
suggested that serum lipoproteins may compete with the 
cells for CS binding or uptake. To assess this hypothesis, 
CS uptake by LCL was examined by incubating the cells 
in the presence of Ultroser-containing medium and increas- 
ing concentrations of human serum low density lipopro- 
teins. Under these conditions, CS uptake by normal as well 
as familial hypercholesterolemia LCL decreased propor- 
tionally to the extracellular concentration of lipoproteins 
(at a concentration f 200/zg apoprotein B/ml, CS uptake 
was reduced by a factor of 3; data not shown). 
Fig. 3 shows the concentration-dependent uptake of CS 
by LCL. In all the cell lines tested, the total cell-associated 
radioactivity increased almost linearly with the concentra- 
tion of exogenous radiolabelled CS (up to 20 pmol/ml; 
Fig. 3A,B). Again, CS uptake levels were higher in the 
absence than in the presence of serum. To study further the 
concentration-dependence of CS uptake, cells were incu- 
bated with radioactive CS and increasing concentrations of 
unlabelled CS. As shown in the inset of Fig. 3B, CS 
uptake by normal, XLI and familial hypercholesterolemia 
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Fig. 5. Outflux of cholesterol sulfate (A) and its conversion to cholesterol (B) in LCL. Intact LCL from 5 normal individuals, low-density lipoprotein 
receptor-deficient (familial hypercholesterolemia; FH), multiple sulfatase deficient (MSD) and XLI patients were incubated with [3H]cholesterol sulfate 
(about 106 dpm/ml)  in medium supplemented with 10% fetal calf serum. After 24 h incubation, cells were washed and further incubated in fresh medium. 
At the indicated time periods of chase, the cells were collected and the lipids were extracted, separated and quantified by TLC as described in Section 2. In 
A, total cell-associated radioactivity (expressed as pmol CS /mg of proteins at the end of the pulse period); in B, amount of [3H]cholesterol formed. This 
experiment was one of three which gave similar results. 
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LCL was linear up to a CS concentration of 100 nmol/ml, 
which is suggestive of cellular entry by simple diffusion. 
3.4. Metabolic fate of cholesterol sulfate by LCL 
The degradation of CS taken up by the cells was 
followed by TLC for quantifying the radioactive lipid 
metabolic products. Only two radioactive bands were ob- 
served on TLC plates, i.e., intact CS and cholesterol. Fig. 4 
reports the amount of radiolabelled cholesterol formed in 
the various LCL after one day incubation with different 
concentrations of CS. In control cells, the cholesterol 
amounts increased quite proportionally to the extracellular 
concentration of CS (Fig. 4). However, it is interesting to 
note that similar amounts of cholesterol were found in 
cells incubated in the absence (Fig. 4A) or presence (Fig. 
4B) of serum (i.e., independently of the total cell-associ- 
ated amount of CS) and that only a minor fraction (about 
10% or less) of CS was hydrolyzed. As expected from 
their deficiency of cholesterol sulfatase activity (see above), 
XLI cells were completely unable to degrade the exoge- 
nously supplied CS (Fig. 4A,B). 
The metabolic fate of both the CS taken up by the cells 
and the subsequently formed cholesterol was examined in 
pulse-chase experiments. As illustrated in Fig. 5A, the total 
cell-associated radioactivity strongly declined with the time 
of chase. This decrease occurred in both control and 
STS-deficient (XLI and MSD) cells, suggesting an outflux 
of CS. The loss of cell-associated radioactivity was not 
simply due to extensive CS degradation since the cellular 
amounts of radioactive cholesterol represented only about 
10% of the total radioactivity at the end of the pulse period 
and gradually decreased after 48 h chase (Fig. 5B). Of 
note, while no radioactive cholesterol was formed in XLI 
cells, low but detectable amounts of cholesterol were 
found in LCL from MSD patients. 
4. Discussion 
The skin disorder XLI has been shown to be associated 
with the combined eficiency of two sulfatases acting on a 
natural steroid sulfate (STS) and a synthetic compound 
(ASC). Up to now, human skin fibroblasts and keratino- 
cytes represent the only experimental models in culture, 
available for studying this disease. The present study is the 
first report on the establishment and enzymatic harac- 
terization of Epstein-Ban" virus-transformed LCL derived 
from patients with XLI. 
LCL from control individuals are shown to exhibit ASC 
and STS activities. These enzyme activities were higher 
than those in blood leukocytes (Table 1) and lymphocytes 
[ 10]. Our data also show that ASC and STS of LCL share 
the same enzyme properties as those of other cells: optimal 
activity at about pH 8.0 and inhibition by phosphate ions 
have also been found in leukocytes [12,17] and skin fibrob- 
lasts [17]. Elsewhere, this study of the enzyme properties 
allowed definition of the optimal conditions for assaying 
ASC and STS and for diagnosing XLI in LCL. 
One ASC isoenzyme has been shown to be identical 
with STS in a variety of tissues [6,7,42]. In accordance 
with previous findings on fibroblasts, our data on LCL 
strongly suggest a very close relationship between ASC 
and STS sulfohydrolases. This is indicated by the follow- 
ing observations: (1) both ASC and STS activities were 
deficient in XLI lymphoblastoid cells, and (2) when com- 
paring different cell lines, the ASC activity closely paral- 
leled that of STS. 
The gene for STS has been assigned to the distal part of 
the short arm of the X-chromosome [2]. Evidence has been 
provided to demonstrate hat the STS gene escapes X-in- 
activation [2], resulting in a dosage inequity between males 
and females. Such a gene-dosage effect has been reported 
for ASC and STS on leukocytes [9,11,12,17], lymphocytes 
[43] and skin fibroblasts [17,41,43,44]. Our studies showed 
a ratio of ASC activity in LCL from females and males of 
1.65 and for STS activity of 1.4. Although the number of 
individuals we examined was too small for a valuable 
statistical analysis, these results on a sex difference are in 
agreement with other observations [ 11,12,17,41,43,44] 
which reported a ratio different from 2:1. As already 
suggested, these data would support he hypothesis for an 
incomplete inactivation of the STS locus in females. 
CS has attracted some attention because, in spite of its 
ubiquitous distribution in mammalian tissues [2], its bio- 
logical roles are still poorly understood. The pathological 
storage of CS in the stratum corneum of patients with STS 
deficiency [20,21] has led to the proposal that excess CS in 
epidermis induces the abnormal desquamation i  XLI [24]. 
Patients with XLI also accumulate CS in erythrocyte mem- 
branes and serum [25,26]. The present study aimed at 
elucidating the mechanisms in XLI which may underlie the 
CS accumulation in the extracellular domain. Thus, the 
mode of uptake and the subsequent metabolic fate of 
radiolabelled CS were investigated in LCL from XLI 
patients and compared to those in control cells. 
As previously observed on skin fibroblasts and kera- 
tinocytes from subjects devoid of XLI [45], CS uptake by 
LCL is not receptor-mediated. Indeed, CS was taken up by 
normal and XLI LCL via a concentration-dependent, non-
saturable process. In addition, although CS can associate 
with lipoproteins [23,26] (see also Section 3), its cellular 
uptake is independent of the low-density lipoprotein-recep- 
tor. The normal rates of CS uptake we noted in LCL 
derived from homozygotes with familial hypercholes- 
terolemia re in good agreement with the observation of 
Williams et al. [23] that CS inhibited sterologenesis in both 
normal and low-density lipoprotein receptor-deficient fi- 
broblasts. Thus, only the non-lipoprotein-associated CS 
seems to be taken up by the cells. 
The present report also demonstrates that, while normal 
cells desulfate CS, intact living LCL from XLI patients are 
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completely unable to degrade CS. A comparable observa- 
tion on intact fibroblasts has already been mentioned in a 
report on the biological effects of CS [22]. Of special 
interest was the finding that, despite their inability for 
conversion of CS to cholesterol, these STS-deficient LCL 
did not accumulate CS due to outflux of the unmetabolized 
sterol. Even in normal LCL where, as noted on normal 
fibroblasts [22], desulfation is a relatively low process, a 
marked efflux of CS occurred. Although this is the first 
report on a 'normal' efflux of CS in cells from XLI 
patients, our data are consistent with a previous observa- 
tion on the CS outflux in normal keratinocytes [45]. It is 
also worth mentioning that, with regard to both the mode 
of uptake and outflux, CS behaves as another sulfated 
lipid, cerebroside sulfate [46]. 
The findings of the present study may have some 
important implications for the pathogenesis of excess CS 
in plasma and epidermis of XLI patients. The release of 
undegraded CS from blood cells (in this respect, LCL 
representing a model for circulating lymphocytes) could 
explain the increased levels of plasma CS in XLI patients 
[25,26]. As extracellular CS partitions into lipoproteins 
[23] (also the present study), this would support the modi- 
fications of low-density lipoproteins observed in the pa- 
tient plasma [26]. As to the question of localization of 
disease to the skin, it has been postulated that excess CS in 
epidermis results from its active epidermal synthesis rather 
than reflection of increased plasma CS content [20,21]. 
Based on the data of the present report, CS could also 
accumulate in the stratum corneum because it is released 
(without degradation) from cells in the extracellular do- 
main and cannot be discharged into the circulation. The 
outflux of CS may then explain why it can modulate the 
metabolism of sterols [22] and non-sterol lipids [23] of 
lower epidermal ayer cells. Another theoretical hypothesis 
for the accumulation of CS in the XLI skin would be that 
the skin defect in XLI resides in an impairment of CS 
outflux only in keratinocytes. Although unlikely (because 
of the CS outflux observed in several cell types and CS 
accumulation in the extracellular domain), this possibility 
still remains to be excluded on XLI keratinocytes. 
Compared with skin fibroblasts (or keratinocytes), LCL 
are extremely useful as a source of immortalized cells, 
both for the in vitro investigation of numerous genetic 
phenomena nd the study of polymorphic disease markers 
[28]. This study has provided evidence for the validity of 
LCL as a new experimental model system in culture for 
studying both the enzymatic and metabolic alterations in 
XLI. 
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